U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06882148) titled 'Drug Survival of Target Therapies in Atopic Dermatitis' on Oct. 10, 2023.
Brief Summary: This is an observational study with drug to evaluate the drug survival of approved target therapies in atopic dermatitis. Patients affected by moderate-severe atopic dermatitis who will start therapy with approved target drugs (dupilumab, tralokinumab, upadacitinib, abrocitinib, baricitinib) for AD will be enrolled. Patients already on therapy with these drugs will also be included.
During the baseline and follow up visits, clinical and demographic data will be collected, according to ordinary clinical practice. Current or retrospective diseas...